Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection

Alimentary Pharmacology and Therapeutics

Volumn 15, Issue 12, 2001, Pages 1959-1965

  Wong, B C Y ^a,d   Wong, W M ^a   Yee, Y K ^b   Hung, W K ^c   Yip, A W C ^c   Szeto, M L ^b   Li, K F ^b   Lau, P ^c   Fung, F M Y ^a   Tong, T S M ^a   Lai, K C ^a   Hu, W H C ^a   Yuen, M F ^a   Hui, C K ^a   Lam, S K ^a  

^a QUEEN MARY HOSPITAL   (Hong Kong)

^b TUEN MUN HOSPITAL   (Hong Kong)

^c KWONG WAH HOSPITAL   (Hong Kong)

^d UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG POTENCY; DRUG TOLERABILITY; ENDOSCOPY; ERADICATION THERAPY; FEMALE; GASTROINTESTINAL INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; AGED, 80 AND OVER; ANTI-ULCER AGENTS; BENZIMIDAZOLES; DIARRHEA; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; DUODENAL ULCER; EXANTHEMA; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PROTON-TRANSLOCATING ATPASES; STOMACH ULCER; TIME FACTORS; TREATMENT OUTCOME;

EID: 0035668317     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2001.01118.x     Document Type: Article

References (26)

1. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection
2. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: The MACH 1 study
3. The MACH 2 study: Role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies
4. Prevalence of metronidazole resistant Helicobacter pylori strains among Chinese peptic ulcer disease patients and normal controls in Hong Kong
5. Review article: The pharmacology of rabeprazole
6. Review article: Comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors
7. In vitro activities of rabeprazole, a novel proton pump inhibitor, and its thioether derivative alone and in combination with other antimicrobials against recent clinical isolates of Helicobacter pylori
8. A novel action of the proton pump inhibitor rabeprazole and its thioether derivative against the motility of Helicobacter pylori
9. Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration
10. Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection - Comparison with omeprazole and lansoprazole
11. Efficacy of reduced dosage of rabeprazole in PPI/AC therapy for Helicobacter pylori infection: Comparison of 20 and 40 mg rabeprazole with 60 mg lansoprazole
12. Rabeprazole, amoxycillin and low- or high-dose clarithromycin for cure of Helicobacter pylori infection
13. 5-day vs. 7-day triple therapy with rabeprazole, clarithromycin and amoxicillin for Helicobacter pylori eradication
14. An evaluation of invasive and non-invasive tests for the diagnosis of Helicobacter pylori infection in Chinese - The best tests for routine clinical use and research purposes
15. One-week ranitidine bismuth citrate-based triple therapy for the eradication of Helicobacter pylori in Hong Kong with high prevalence of metronidazole resistance
16. Comparison of lansoprazole-based triple and dual therapy for treatment of Helicobacter pylori-related duodenal ulcer: An Asian multi-center prospective double blind randomized placebo controlled study
17. The importance of clarithromycin dose in the management of Helicobacter pylori infection: A meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole
18. The DU-MACH study: Eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy
19. GU-MACH study: The effect of 1-week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcer
20. Triple therapy with clarithromycin, omeprazole, and amoxicillin for eradication of Helicobacter pylori in duodenal ulcer patients in Asia and Africa
21. High prevalence of Helicobacter pylori infection with dual resistance to metronidazole and clarithromycin in Hong Kong
22. Four day triple therapy with rabeprazole, amoxycillin and clarithromycin in the eradication of Helicobacter pylori in patients with peptic ulcer disease - A pilot study
23. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection
24. Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: The MACH 2 study
25. Impact of Helicobacter pylori resistance to clarithromycin on the efficacy of the omeprazole-amoxicillin-clarithromycin therapy
26. Three-day quadruple therapy is effective in treatment of Helicobacter pylori-related duodenal ulcers